Belgium-based UCB selected Gwinnett County, Georgia, as the location for its new U.S. biologics manufacturing facility. The campus will use a digital-first approach by leveraging AI, robotics, and ...
The MarketWatch News Department was not involved in the creation of this content. -- New Gwinnett County facility will strengthen UCB's global biologics manufacturing network and support growing ...
FILE - The North American headquarters of Belgian pharmaceutical company UCB is seen, Nov. 10, 2014, in Smyrna, Ga. (Paul Abell/AP Images for UCB, Inc., File) (Paul Abell) ATLANTA – Belgian ...
UCB plans to build a $2 billion manufacturing facility near its U.S. headquarters in Atlanta, Georgia. It will become the first plant in the U.S. for the Belgium-based company and will produce ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
ATLANTA (AP) — Belgian pharmaceutical company UCB announced Tuesday that it would invest $2 billion to build a drug-making plant in suburban Atlanta. The rapidly growing drugmaker said the plant, ...
Belgian biopharma company UCB (UCBJY) announced on Wednesday that its arthritis therapy Bimzelx outperformed AbbVie’s (ABBV) immunology therapy Skyrizi in a head-to-head trial for psoriatic arthritis, ...
UCB has entered the red-hot T-cell engager (TCE) space by paying $80 million for the rights to a Chinese biotech’s preclinical autoimmune candidate. At the center of the deal is ATG-201, a CD19/CD3 ...
Belgian drugmaker UCB has entered into an agreement to licence Antengene's (6996.HK), opens new tab experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results